A broad look at the relationship between valuation movement and headcount changes over a 10 year period for the top 15 biopharma companies by 2022 employee numbers reveals by-and-large what one would expect for these big, deal-making entities. Increases in employee numbers often go hand-in-hand with valuation rises as companies are acquired or product success necessitate increases to sales-staff or manufacturing capacity. However, there are a few standouts.
Value Versus Headcount: What Do The Numbers Show?
Analysis Reveals Four Companies Made Over $1m Per Employee
Increases in employee numbers often go hand-in-hand with valuation rises as companies are acquired or product success demand increases in sales staff or manufacturing capacity. However, this is not always the case.
More from Growth
More from In Vivo
• By
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
• By
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.